M E Boursnell
Overview
Explore the profile of M E Boursnell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Loudon P, Blakeley D, Boursnell M, Day D, Duncan I, Lowden R, et al.
J Gene Med
. 2001 Oct;
3(5):458-67.
PMID: 11601759
Background: DISC-hGMCSF is a gH-deleted HSV-2 based vector expressing human GM-CSF that is being developed for cancer immunotherapy. To support first clinical use, a range of preclinical safety studies were...
2.
Ali S, McLean C, Boursnell M, Martin G, HOLMES C, Reeder S, et al.
Cancer Res
. 2000 Apr;
60(6):1663-70.
PMID: 10749137
The development of genetically modified "whole" tumor cell vaccines for cancer therapy relies on the efficient transduction and expression of genes by vectors. In the present study, we have used...
3.
Zhang X, De Alwis M, Hart S, Fitzke F, Inglis S, Boursnell M, et al.
Hum Gene Ther
. 1999 Oct;
10(15):2527-37.
PMID: 10543617
Production of high-titer rAAV is essential for in vivo clinical application. One limiting factor may be the failure of existing systems to replicate the packaging genome in such a way...
4.
Disabled infectious single cycle (DISC) herpes simplex virus as a vector for immunotherapy of cancer
Boursnell M, Entwisle C, Ali S, Sivasubramaniam S, Reeder S, McLean C, et al.
Adv Exp Med Biol
. 1999 Feb;
451:379-84.
PMID: 10026900
No abstract available.
5.
Hill S, Zhang X, Boursnell M, Shields J, Ricciardi-Castagnoli P, Hickling J
Biochem Soc Trans
. 1997 May;
25(2):200S.
PMID: 9191244
No abstract available.
6.
Boursnell M, Entwisle C, Blakeley D, Roberts C, Duncan I, Chisholm S, et al.
J Infect Dis
. 1997 Jan;
175(1):16-25.
PMID: 8985191
A glycoprotein H (gH)-deleted herpes simplex virus type 2 (HSV-2) was evaluated as a vaccine for the prevention of HSV-induced disease. This virus, which we term a DISC (disabled infectious...
7.
Boursnell M, Rutherford E, Hickling J, Rollinson E, Munro A, Rolley N, et al.
Vaccine
. 1996 Nov;
14(16):1485-94.
PMID: 9014288
The presence and consistent expression of the genes encoding the human papillomavirus (HPV) E6 and E7 proteins in the great majority of cervical tumours presents the opportunity for an immunotherapeutic...
8.
McLean C, Ni Challanain D, Duncan I, Boursnell M, Jennings R, Inglis S
Vaccine
. 1996 Jul;
14(10):987-92.
PMID: 8873393
The vaccine potential of a genetically disabled Herpes Simplex Virus Type 1 virus (DISC HSV-1) was investigated in the guinea pig model of intravaginal (i.vag.) HSV-2 infection. Three mucosal vaccination...
9.
Borysiewicz L, Fiander A, Nimako M, Man S, Wilkinson G, Westmoreland D, et al.
Lancet
. 1996 Jun;
347(9014):1523-7.
PMID: 8684105
Background: Human papillomavirus (HPV) infection, especially with type 16 or 18, is associated with cervical cancer. Two HPV proteins, E6 and E7, are consistently expressed in tumour cells. The objectives...
10.
McLean C, Erturk M, Jennings R, Challanain D, Minson A, Duncan I, et al.
J Infect Dis
. 1994 Nov;
170(5):1100-9.
PMID: 7963701
The vaccine potential of a mutant herpes simplex virus (HSV) type 1, with a deletion in the glycoprotein H (gH) gene, was evaluated. The virus requires a gH-expressing cell line...